[8-K] SunLink Health Systems, Inc Reports Material Event

Rhea-AI Filing Summary

SunLink Health Systems, Inc. (NYSE American: SSY) filed an 8-K (Item 8.01) dated 24 Jul 2025 reporting the release of a press announcement tied to its pending merger with Regional Health Properties, Inc.

• Record date: 20 Jun 2025; shareholders are urged to submit proxy votes no later than 28 Jun 2025, 11:59 p.m. EDT.
• Regional has already filed a Form S-4 containing the joint proxy statement/prospectus, mailed on or about 30 Jun 2025.
• The press release is furnished as Exhibit 99.1; an Inline XBRL cover file is provided as Exhibit 104.
• The filing reiterates that it is not an offer to sell securities and directs investors to obtain free copies of the proxy materials via the SEC or company websites.

The remainder of the report consists of forward-looking-statement disclaimers outlining risks such as potential litigation, integration hurdles, listing-requirement compliance, and macroeconomic headwinds. No financial statements or operating results are included.

Positive

• Shareholder vote scheduled for 28 Jun 2025 demonstrates the merger process is advancing on a defined timetable.
• Form S-4 and joint proxy statement have already been mailed, showing regulatory filings are substantially complete.

Negative

• Extensive risk disclosures emphasise litigation, integration, and listing-compliance uncertainties that could derail or delay the merger.
• No new financial or synergy metrics were provided, leaving investors without updated economic justification for the deal.

Insights

M&A Specialist

TL;DR: Procedural 8-K: merger timetable intact; shareholder vote on 28 Jun 2025 remains key hurdle amid stated legal and integration risks.

The filing is chiefly administrative, serving to remind SunLink investors to cast their proxies on the Regional Health combination. Distribution of the Form S-4 and joint proxy statement indicates regulatory progress, but completion still depends on majority approvals and satisfaction of NYSE American and OTCQB listing standards. The expansive risk section—litigation exposure, integration complexity, revenue synergies, and macro factors—highlights substantial execution uncertainty. With no new valuation data or revised terms, the disclosure is neutral for deal odds but signals management’s commitment to move the transaction forward on schedule.

0000096793false00000967932025-07-242025-07-24

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

	Date of report (Date of earliest event reported): July 24, 2025
	SunLink Health Systems, Inc.
	(Exact Name of Registrant as Specified in its Charter)
Georgia	001-12607	31-0621189
(State or Other Jurisdiction of	(Commission	(I.R.S. Employer
Incorporation)	File Number)	Identification No.)
	900 Circle 75 Parkway
	Suite 690
	Atlanta, Georgia 30309
	(Address of Principal Executive Offices, and Zip Code)
	(770) 933-7000
	(Registrant’s telephone number, including area code)

Not applicable.

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

x Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, no par value	SSY	NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

On July 24, 2025, SunLink Health Systems, Inc. (NYSE American: SSY) issued a press release to provide an update on proxy voting for the proposed merger with Regional Health Properties, Inc. and to urge SunLink stockholders of record as of June 20, 2025 to vote by June 28, 2025, at 11:59 PM EDT. A copy of this press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit
Number						Description
99.1						Press Release dated July 24, 2025
104						Cover Page interactive data file (embedded within the Inline XBRL document)

* * *

NO OFFER OR SOLICITATION

Communications in this Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any proxy vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the “Securities Act”).

ADDITIONAL INFORMATION

The proposed merger will be submitted to both the Regional and SunLink shareholders for their consideration. In connection with the proposed merger, Regional filed a Registration Statement on Form S-4 (as supplemented or amended, the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) that includes a joint proxy statement/prospectus for Regional and SunLink (the “joint proxy statement/prospectus”), which was sent to common stock shareholders of Regional and common stock shareholders of SunLink on or about June 30, 2025.

INVESTORS ARE URGED TO READ THE REGISTRATION STATEMENT AND THE CORRESPONDING JOINT PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED MERGER, AS WELL AS ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, TOGETHER WITH ALL AMENDMENTS AND SUPPLEMENTS TO THOSE DOCUMENTS, AS THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION.

You are able to obtain a copy of the joint proxy statement/prospectus, as well as other filings containing information about SunLink and Regional, without charge, at the SEC’s website (http://www.sec.gov) or by accessing SunLink’s website (http://www.sunlinkhealth.com) under the tab “Investors” or by accessing Regional’s website (http://www.regionalhealthproperties.com) under the tab “Investor Relations.” Copies of the joint proxy statement/prospectus have been mailed to the shareholders of SunLink and Regional who are, as of the respective record dates, entitled to vote on the Merger, copies can also be obtained, without charge, by directing a request to Investor Relations, SunLink Health Systems, Inc., 900 Circle 75 Parkway, Suite 690, Atlanta, Georgia, 30339,

1

telephone 770-933-7004 or to Investor Relations, Regional Health Properties, Inc., 1050 Crown Pointe Parkway, Suite 720, Atlanta, Georgia, 30338, telephone 678-869-5116.

SunLink and Regional and certain of their directors and executive officers may be deemed to be participants in the solicitation of proxies from the shareholders of SunLink and Regional in connection with the proposed Merger. Information about the directors and executive officers of SunLink is set forth in Part III of SunLink’s Amendment No. 1 to Annual Report on Form 10-K for the fiscal year ended June 30, 2024, which information may be updated by SunLink from time to time in subsequent filings with the SEC. Information about the directors and executive officers of Regional is set forth in Part III of Regional’s Annual Report on Form 10-K for the year ended December 31, 2024, which information may be updated by Regional from time to time in subsequent filings with the SEC. Additional information about the interests of those participants and other persons who may be deemed participants in the transaction may also be obtained by reading the joint proxy statement/prospectus relating to the proposed Merger. Free copies of this document may be obtained as described above.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements can often, but not always, be identified by the use of words like “believe”, “continue”, “pattern”, “estimate”, “project”, “intend”, “anticipate”, “expect” and similar expressions or future or conditional verbs such as “will”, “would”, “should”, “could”, “might”, “can”, “may”, or similar expressions. These forward-looking statements include, but are not limited to, statements relating to the expected timing and benefits of the proposed Merger between Regional and SunLink, including statements of Regional’s goals, intentions and expectations; statements regarding Regional’s business plan and growth strategies; and the ability of Regional to meet the continued listing requirements of the NYSE American and to maintain the listing of securities thereon.

These forward-looking statements are subject to significant risks, assumptions and uncertainties that may cause results to differ materially from those set forth in forward-looking statements, including, among other things:

•Litigation that may be filed against Regional, SunLink, the members of the Regional Board, the members of the SunLink Board or the officers of Regional or SunLink could result in substantial costs, and the possible unexpected or adverse outcomes of such litigation, any of which could adversely affect Regional’s and SunLink’s ability to complete the Merger on a timely basis or at all;

•the ability to obtain the approvals of SunLink’s or Regional’s shareholders, and the ability to complete the Merger on the expected timeframe;

•the ability of SunLink to meet the continued listing requirements or rules of the NYSE American LLC, the ability of Regional to meet the requirements of the OTCQB, and the ability of Regional to meet the initial listing requirements of the NYSE American after the Merger, and, as applicable, the ability to maintain the listing or trading, as applicable, of securities thereon;

•the risk that the businesses of Regional and SunLink will not be integrated successfully, or such integration may be more difficult, time-consuming, or costly than expected;

•expected revenue synergies and cost savings from the Merger may not be fully realized or realized within the expected time frame;

•revenues following the Merger may be lower than expected;

•customer, vendor and employee relationships and business operations may be disrupted by the Merger;

•possible changes in economic and business conditions;

•the impacts of epidemics, pandemics, or other infectious disease outbreaks;

•the existence or exacerbation of general geopolitical instability and uncertainty;

•possible changes in monetary and fiscal policies, and laws and regulations;

2

•competitive factors in the healthcare industry;

•Regional’s dependence on the operating success of its operators;

•the amount of, and Regional’s ability to service, its indebtedness;

•covenants in Regional’s debt agreements that may restrict its ability to make investments, incur additional indebtedness, and refinance indebtedness on favorable terms;

•the effect of increasing healthcare regulation and enforcement on Regional’s operators and the dependence of Regional’s operators on reimbursement from governmental and other third-party payors;

•the relatively illiquid nature of real estate investments;

•the impact of litigation and rising insurance costs on the business of Regional’s operators;

•the effect of Regional’s operators declaring bankruptcy, becoming insolvent, or failing to pay rent as due;

•the ability of any of Regional’s operators in bankruptcy to reject unexpired lease obligations and to impede its ability to collect unpaid rent or interest during the pendency of a bankruptcy proceeding and retain security deposits for the debtor’s obligations;

•Regional’s ability to find replacement operators and the impact of unforeseen costs in acquiring new properties; and

•other risks and factors identified in (i) SunLink’s cautionary language included under the headings “Forward-Looking Statements” and “Risk Factors” in SunLink’s Annual Report on Form 10-K for the year ended June 30, 2024, and other documents subsequently filed by SunLink with the SEC and (ii) Regional’s cautionary language included under the headings “Statement Regarding Forward-Looking Statements” and “Risk Factors” in Regional’s Annual Report on Form 10-K for the year ended December 31, 2024, and other documents subsequently filed by Regional with the SEC.

Neither SunLink nor Regional undertake any obligation to update any forward-looking statement, whether written or oral, relating to the matters discussed in this Current Report on Form 8-K. In addition, SunLink’s and Regional’s past results of operations do not necessarily indicate either of their anticipated future results, whether the Merger is effectuated or not.

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SUNLINK HEALTH SYSTEMS, INC.
Date: July 25, 2025	/s/ Mark J. Stockslager
	Mark J. Stockslager
	Chief Financial Officer

4

FAQ

When must SSY shareholders vote on the Regional Health merger?

Proxy votes are requested by 28 June 2025, 11:59 p.m. EDT.

What is the record date for SunLink’s merger vote?

Only holders of record as of 20 June 2025 are entitled to vote.

Where can investors access the joint proxy statement/prospectus for SSY?

Free copies are available on the SEC’s EDGAR system and on SunLink’s and Regional’s investor-relations webpages.

Which exhibit in the 8-K contains the related press release?

The press release is filed as Exhibit 99.1.

Does the 8-K include any new financial results for SunLink?

No. The filing contains no financial statements or earnings data; it is limited to merger-related voting information.